IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers.

Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.

It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers.

The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.

IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.